-
FDA declines to approve Brilinta
WILMINGTON, Del. — The Food and Drug Administration has turned down AstraZeneca’s regulatory approval application for a drug to treat heart disease, the drug maker said.
The agency sent AstraZeneca a complete response letter requesting additional analyses of data from a clinical study of Brilinta (ticagrelor), but did not request additional studies. The drug is designed to treat acute coronary syndromes.
A complete response letter means that the FDA has completed its review of a drug application, but issues remain that preclude final approval.
-
Frank Baldino, Cephalon leader, dies at 57
FRAZER, Pa. — Frank Baldino, the founder, chairman and CEO of Cephalon, has died, the company said.
Cephalon announced that Baldino, 57, had died Thursday evening while on medical leave, calling him a pioneer in the biotechnology industry and an inspirational leader who would be “sorely missed.” Baldino, who received his doctorate in pharmacology from Temple University, founded the company in 1987 after several years at E.I. duPont de Nemours & Co.